Amphivena Therapeutics, a developer of immunotherapeutics, is on a mission to eradicate blood cancers. Their goal is to restore the flow of life by reestablishing cellular balance. Amphivena Therapeutics believes that if blood is forming, functioning, and circulating properly then the body’s immune system will destroy tumors along with their precursors.
The San Francisco-based company, founded in 2013, is currently in the pre-clinical stage of development. Amphivena Therapeutics INC. is an innovative company that formed relationships with world renowned industry and academic associates. They are committed to giving patients suffering from hematologic malignancies the best treatment options available.
Leading the company’s foray into unchartered immunotherapy territory is the incredible JeanMarie Guenot, Ph.D. Dr. Guenot is the current President and CEO of Amphivena Therapeutics. She has 20 years of experience in both the biotechnology and the pharmaceutical industry. JeanMarie Guenot also has an unprecedented amount of experience in building and rebuilding companies. Something that will most likely prove to be invaluable to an innovator like Amphivena.
JeanMarie Guenot began her education at the University of California, San Francisco, where she studied medicinal chemistry, physical chemistry, quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design. She received her Ph.D. and went on to study at the University of Pennsylvania’s prestigious Wharton School, where she earned her MBA.
JeanMarie’s biography makes it clear that after being employed as a venture capital investment manager and life science company developer at Atlas Venture, and as a principal scientist at Hoffmann-La Roche, Dr. Guenot founded SKS Ocular. SKS Ocular is a start-up ophthalmic company incubator, focused on sustained release ocular drug delivery technologies, dry AMD, and glaucoma, macular degeneration and ocular inflammation therapies.
Dr. Guenot is clearly passionate about her life’s work. She’s capable of leading Amphivena Therapeutics to the forefront of immunotherapeutics. Read more about Guenot’s work with Amphivena on Newson6.